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Background: Adherence to medication is often low. Pharmacists may improve adherence, but a one-size-fits-all
approach will not work: different patients have different needs. Goal of the current study is to assess the effectiveness
of a patient-tailored, telephone-based intervention by a pharmacist at the start of pharmacotherapy aimed at improving
medication adherence, satisfaction with information and counselling and the beliefs about medicines.
Methods/Design: A cluster randomized controlled intervention trial in 30 Dutch pharmacies, randomly assigned to 1
of 2 intervention groups. Each group consists of an intervention arm and an usual care arm. The intervention arm in
the first group is the usual care arm in the second group and vice versa. One intervention arm focuses on patients
starting with antidepressants or bisphosphonates and the other on antilipaemic drugs or renin angiotensin system
(RAS)-inhibitors. The intervention consists of a telephone call by a pharmacist 2 or 3 weeks after a new
prescription. A random sample of pharmacies will send questionnaires 3 months after the first prescription. This
contains socio-demographic questions, a measure of beliefs about medicines (BMQ), satisfaction with information
received (SIMS, abbreviated) and frequency of pharmacy counselling (Consumer Quality Index, CQI, abbreviated).
The primary outcome measure will be medication adherence calculated from dispensing records retrieved
12 months after the intervention. Patients’ beliefs on medication, perception of the quality of information received
and pharmacy counselling are secondary outcomes.
Discussion: The TelCIP study will determine the effectiveness of telephone counselling to improve adherence in
patients initiating a new treatment. By measuring satisfaction with information and counselling and beliefs about
medication the study will also give clues for the reason of a potential increase in adherence. Finally the study will
provide information on which patients are most likely to benefit from this intervention.
Trial registration: The trial is registered at www.trialregister.nl under the identifier NTR3237.
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Adherence to medication therapy in general is often low
[1-3]. Non-adherence to long-term therapies severely
compromises the effectiveness of treatment and is there-
fore critical from both the perspective of quality of life of
individual patients and from the perspective of public
health and health economics. There are many different fac-
tors involved in non-adherence including social and eco-
nomic factors, the characteristics of the disease and its
therapy and health-care provide related factors and patient-
related factors such as beliefs about medicines [3-6].
Urquhart et al. and more recently Vrijens et al. argued that
three phases of chronic drug treatment can be identified:
acceptance of the treatment plan, implementation of the
drug regimen and eventually complete discontinuation
(non-persistence) of treatment [7,8]. Non-adherence can
take place in these three different stages [8].
Non-adherence cannot be regarded as an isolated prob-
lem of the patient. The health care provider has to support
patients to improve adherence. Patients need information
about their medicines to facilitate their appropriate use and
understanding of the benefits and risks [5,9,10]. Providing
patients with appropriate information about medication
has been associated with improved adherence resulting in
improved treatment outcomes. In contrast, information not
addressing patients’ needs may produce opposite effects
[11,12]. A great part of the information provided by the
healthcare practitioner is forgotten or remembered incor-
rectly [13,14]. Therefore it would be desirable to consider
repeated opportunities for providing information [15]. But
providing information alone is not enough: patients need to
be motivated and be involved in decision making [16].
Negative attitudes and barriers that prevent adherent be-
haviour should be addressed.
Different interventions have been studied to improve
adherence. Multidisciplinary and multifactorial interven-
tions were more effective than single focus-interventions.
Ideally interventions should focus on practical and per-
ceptual barriers that affect adherence. Practical barriers
may include complex dosage regimens, the size of tablets,
the cost of prescriptions, the route of delivery (e.g. rectal or
oral) and side effects. In contrast, perceptual barriers are
more complex and are based on an internal negotiation be-
tween the perceived necessity of the treatment and any
concerns relating to it. Interpersonal communication pro-
vides opportunity to tailor information to the practical and
perceptual barriers of a specific patient [17,18].
Pharmacists can play an important role in improving
adherence: they are easily accessible health-care providers,
have frequent contacts with patients, have extensive
knowledge about drug therapy and are equipped to pro-
vide information and monitor patients’ experiences and
adherence at visit to the pharmacy. However, it is not al-
ways possible to tailor counselling to patient needs [10].Some patients are unable to visit the pharmacy. Others
perceive a lack of privacy in the pharmacy or do not have
time for counselling at the moment of the visit. Sometimes
patients are already overwhelmed by information provided
by other health care providers and therefore not open to
receive additional information from the pharmacy.
A different approach might improve patient counselling.
Counselling by telephone has proven to be an effective, easy
implementable alternative [19,20]. Although it has some
disadvantages like the lack of non-verbal communication, it
can resolve some of the barriers mentioned above. The pa-
tient is counselled in his or her own safe environment and
lack of privacy is not an issue. From the health care pro-
viders’ perspective: it is easier to implement since the calls
can be scheduled. Competent employees can be appointed
and can better anticipate on the subject.
Given the above we designed an intervention aimed at
preventing patients initiating treatment from becoming
non-adherent. We will focus on patient starting with lipid
modifying agents, Renin-Angiotensin-System (RAS)-inhibi-
tors, antidepressants or bisphosphonates. We choose these
medications because (1) they are intended for long-term
use, (2) are prescribed frequently enough to enable the in-
clusion of a sufficient number of patients during the study
period, (3) adherence is often low and (4) the characteris-
tics of patients using antidepressants, bisphosphonates or
RAS-inhibitors/lipid lowering drugs are different and pa-
tients might weigh risks and benefits of these four groups
of medicines differently.
The main objective of the study is to assess the effective-
ness of a patient-tailored, telephone intervention by a
pharmacist at the start of pharmacotherapy on (1) adher-
ence, (2) beliefs about medicines and (3) satisfaction with
information and counselling. We also will assess to what
extent counselling by telephone fulfils patients’ needs.
Methods and design
Study design
We will conduct a multicentre community pharmacy-
based, cluster randomized controlled trial (CRT) (Figure 1).
Pharmacies are alternately assigned to either group A or
group B in a 1:1 ratio. Given the nature of the study design
it is impossible for both the researchers and the pharma-
cists to be blinded to the group assignment. Each group
consists of an intervention (TelCIP) arm and a usual care
arm. The TelCIP arm in group A focuses on the same
medication as the usual care arm in group B and vice versa.
We performed a pilot in three pharmacies in the period
of October 2010 to December 2010. In this pilot we tested
the manuals, the feasibility, the software to select the pa-
tients (queries) and the online registration form. This pilot
led to some practical adjustments in the manuals, the soft-
ware and the online registration form. The design and the
intervention proved to be feasible.
Figure 1 Study design. Pharmacies are randomized in two groups. Each group consists of an intervention (TelCIP) arm and a usual care arm.
The TelCIP arm in group A focuses on the same medication as the usual care arm in group B and vice versa.
Kooy et al. BMC Health Services Research 2014, 14:219 Page 3 of 9
http://www.biomedcentral.com/1472-6963/14/219Recruitment of pharmacies
Independent pharmacies franchisees of ‘Service Apotheek’
are invited to participate in the study. The study design is
presented at 4 regional meetings for pharmacies where
they could apply for participation. In a weekly newsletter
pharmacies are also invited to participate in the study. The
pharmacies are periodically visited by staff of the franchise
formula and during these visits; the study is also brought
to the attention of the pharmacist. Participating health
care providers have to follow an e-learning communica-
tion training based on the Health Belief Model. The
Health Belief Model (HBM) suggests that adherence be-
haviour is influenced by perceived severity (beliefs about
how severe the condition is), perceived susceptibility (the
extent to which the patient feels at risk of suffering from
the condition) and the effects and disadvantages of the ad-
vised behaviour [21,22]. The course aims to train pharma-
cists and technicians to understand the opinions and
behaviour of patients (related to medication intake). Fur-
thermore the training aims to familiarize pharmacists with
the concept of concordance. The course also pays atten-
tion to sources for information for patients, possibilities
and limitations of package leaflet and the package labels.
The course takes about three hours, includes case studies
and a concluding test to assess the level of theoretical
knowledge on communication and concordance.
Recruitment of patients
Patients starting with treatment will be recruited from
30 community pharmacies in different areas of The
Netherlands in the period between May 2011 and
March 2013.Patients in the intervention arm will be selected through
an automated selection procedure and presented to the
pharmacist. This selection is based on dispensing data and
most inclusion and exclusion criteria are incorporated.
The same selection will be used to include patients in the
usual care group. However not all exclusion criteria can
be incorporated in the automated selection and after se-
lection, pharmacist can decide not to include a patient.
We will ask the pharmacist to register the reason. How-
ever due to the study design the possibility of introducing
a selection bias exists, and therefore our primary analysis
will be based on the intention-to-treat principle (ITT). Pa-
tients will be included in the analysis if they are eligible ac-
cording to selection criteria based on the pharmacy data.
In a per-protocol (PP) analysis we will compare the pa-
tients who actually received counselling with patient who
received usual care.
Inclusion criteria
 Receiving medication for a chronic condition for the
first time in 12 months:
 Intervention arm A: starting with an antidepressant
or bisphosphonate
 Intervention arm B: starting with a Renin-
Angiotensin-System (RAS)-inhibitor or lipid-
lowering drug.
Exclusion criteria
 Under 18 years of age
 Not responsible for their own medication intake
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dispensing system or multi-compartment dispensing
system (e.g. Baxter system or ‘pill organiser’)
 Switching to other medication within the ATC3-
group in the 12 months before inclusion
 Receiving medication for a short term indication
(e.g. antidepressant for smoking cessation)
 Patients not speaking Dutch nor another language
spoken fluently by the healthcare provider
 Patients starting in the same week with both a
medication from intervention arm A (antidepressant
or bisphosphonate) and a medication from arm B
(RAS-inhibitor or lipid-lowering drug).
 Patients without access to a telephone.
Patients in the TelCIP-arms meeting all eligibility cri-
teria receive an information letter, are invited for the
study participation and asked for informed consent.
Medication
The definition of the four different classes of medication is
described in detail in Additional file 1. We include antide-
pressants, bisphosphonates, RAS-inhibitors and lipid low-
ering drugs. Patients switching within a drug class are
excluded. For example when a patient switches from an
ACE inhibitor to an Angiotensin II antagonist, the patient
is not selected.Ethics
The Medical Ethics Review Committee (METC) of the
University Medical Centre Utrecht has considered our re-
search proposal in a meeting 13 July 2010 and concluded
that the Dutch Medical Research Involving Human Sub-
jects Act (WMO) was not applicable. Consequently the
protocol was submitted to the Institutional Review Board
(IRB) of UPPER, Utrecht University and they approved
the study protocol. The trial was registered at www.
trialregister.nl under the identifier NTR3237.Usual care
Usual care in most Dutch pharmacies is as follows: at
the presentation of a first prescription for new medica-
tion, the pharmacist or technician provides the patients
with spoken and written information about the medica-
tion and the disease. Instruction protocols are available
and can be used. A first prescription is generally pro-
vided for a maximum of two weeks. Guidelines recom-
mend that at the first refill, patients are asked about
their experiences with the medication. If necessary, add-
itional information or counselling should be provided.
Guidelines for counselling at the first refill, however, are
not generally implemented.Intervention
The intervention consists of a counselling call by a
pharmacist or a competent technician in addition to usual
care. The call is supported by a pre-tested interview proto-
col. For all medication groups a protocol is developed that
describes the specific instructions or side effects for that
specific group. For example for antidepressants it is men-
tioned that it can take up to 4–6 weeks to notice an effect.
In Additional file 2 a translated version is presented. The
focus in the protocol lies on both practical and perceptual
barriers to take medication. The need for information
about the indication, instructions, side effects and treat-
ment plan will be assessed. Also concerns about the treat-
ment, side effects and dependence will be discussed. The
pharmacist will also inquire about the experiences with
medication intake during the first 2 weeks of treatment
(for example if the patient managed to take the medica-
tion, or experienced any possible side effect). The call
takes place 7 to 21 days after the first prescription. If ne-
cessary the pharmacist will provide information, motivate
the patient, help the patient to find a strategy to be adher-
ent or refer the patient to the physician. After the tele-
phone call the pharmacist registers all topics that have
been discussed in an online database.
Follow up
Dispensing data will be extracted from the pharmacy infor-
mation system. In The Netherlands all prescriptions are
registered in an administrative database, including date of
prescription, number of prescribed tablets, prescriber and
dosage regimen. A selection of pharmacies will collect data
on patient beliefs and satisfaction with information and
pharmacy counselling through a written questionnaire. In
the selected pharmacies a questionnaire will be sent to pa-
tients in both arms, three months after the first prescrip-
tion. The timeline per patient is shown in Figure 2.
Qualitative analysis of calls
To assess to which extent the pharmacist explores barriers
that negatively influence adherence we will record a sam-
ple of telephone consultations. These recordings allow a
direct analysis of communication without relying on par-
ticipant reports or simulated situations [23]. In an amend-
ment the Institutional Review Board of the division of
Pharmacoepidemiology and Clinical Pharmacology of
Utrecht University approved the collection of data.
Patients in the intervention arm meeting all eligibility
criteria who give informed consent, are asked for per-
mission to record the consultation.
Outcomes
Primary outcome
The primary outcome is the proportion of adherent pa-
tients, based on refill adherence. Refill adherence will be
Figure 2 Timeline per patient.
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360 days following the index date by dividing the total
days’ supply by the number of days of study participation
(PDC360) [24].
The index date is the date of the first prescription.
The total days supplied will be calculated as the sum of
days dispensed within the study period. If a supply ex-
ceeds the end of the study participation, this supply will
be corrected for exceeding the end of the period. The
number of days of study participation is defined as the
number of days between the index date and the index
date + 360 or the last refill date, whichever comes first.
For assessing the last refill date, all refills for any drug
will be included. We analyse refill adherence both as
a continuous measure and as a dichotomous measure
with a threshold of 80%. Patients with a PDC360 < 80%
are defined as non-adherent and patients with a
PDC360 ≥ 80% are defined as adherent.
Secondary outcomes
Discontinuation Discontinuation is defined as having a
gap of more than 89 days with no medication available
within the one year observation period. Cox-proportional
hazards will be used to compare discontinuation rates be-
tween intervention and control patients.
Beliefs about medicines Patients’ beliefs about medi-
cines will be assessed using the beliefs about medicines
questionnaire- specific (BMQs) [25], sent to a random
sample of patients three months after the start of ther-
apy. The BMQs assesses both the necessity and concerns
regarding prescribed medication. In the questionnaire
the name of the specific drug is mentioned in the intro-
duction and wherever it is needed. So for example when
a patient starts with simvastatin, one of the BMQ ques-
tions will be “I sometimes worry about the long term ef-
fects of simvastatin”. Five items of the questionnaire
assesses the beliefs about the necessity and five items
assesses the concerns. Each item of the BMQ is scored
using a 5-point Likert scale (1 = strongly disagree, 2 = dis-
agree, 3 = uncertain, 4 = agree, 5 = strongly agree) there-
fore the individual score ranges from 5 to 25. The results
will be expressed as the score on both domains and as thenecessity-concerns differential which is the difference be-
tween the score on the necessity scale and the concern
scale. The results will also be expressed using the two sep-
arate scales, divided at the median to generate four attitu-
dinal groups: accepting (high necessity, low concerns),
ambivalent (high necessity, high concerns), sceptical (low
necessity, high concerns) and indifferent (low necessity,
low concerns) [26-28].
Satisfaction with information The satisfaction with in-
formation provided by healthcare providers like phar-
macists can be assessed with the satisfaction with
information about medicines scale (SIMS). As with the
BMQ, the name of the specific drug was mentioned in
the questionnaire. We used 9 of the 17 items of the ori-
ginal questionnaire [29]. Each item refers to a particular
aspect of medicine use. Not all items are used; firstly be-
cause some items are not relevant for all four groups of
medication, for example “Whether the medication will
make you feel drowsy” and “Whether the medication
will affect your sex life”. Asking patients these questions
when they are not relevant can increase the concerns
and thereby influence adherence. Secondly our goal is not
to assess the satisfaction in general, but to study the effect
of the intervention on satisfaction with information.
Thirdly we want to reduce the total number of questions
in the questionnaire. We use the items as mentioned in
Table 1. We are interested in the effect of the intervention
on specific subjects of information and not in an overall
satisfaction score. Validation of the combination of the
items is therefore not relevant to our study.
Patients are asked to rate the amount of the informa-
tion received as follows: “too much”, “about right”, “too
little”, “none received” and “none needed”. To assess a
total satisfaction rating, for each item a score is calcu-
lated: if the patient is satisfied (answered “about right”)
a score of 1 is given. When the patient is not satisfied
(answered “too much”, “too little”, “none needed” or
“none received”) this is scored 0. So scores range from 0
to 9, with a high score indicating a high degree of satis-
faction. We will calculate a satisfaction score on the
same way but based on patients who answered “none
received” and “none needed”.
Patient’s experience with counselling The question-
naire contains 4 items adapted from the consumer quality
index (CQI) pharmaceutical care [30,31]. In these items
the overall experience of different aspects of counselling
related to the new medication, is assessed (see Table 2). In
the original CQI the patient can answer on a 4-point
Likert scale (“never”, “sometimes”, “often”, and “always”).
But since we are only interested in the counselling in the
first three months since the start of therapy, patients are
offered to indicate “yes”, “no” or “I don’t remember”.





1 How long it will take to act. 5
2 How you can tell if it is working. 6
3 How long you will need to
be on your medicine.
7
4 How to get a further supply. 9
5 Whether the medicine has
any unwanted effects (side effects)
10
6 What are the risks of you getting side effects. 11
7 What you should do if you
experience unwanted side effects
12
8 Whether the medicine
interferes with other medicines.
14
9 What you should do if you
forget to take a dose.
17
Excluded items:
What your medicine is called. 1
What your medicine is for. 2
What it does. 3
How it works. 4
How to use your medicine. 8
Whether you can drink alcohol
whilst taking this medicine
13
Whether the medication will
make you feel drowsy.
15
Whether the medication will
affect your sex life.
16
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“yes”) will be scored 1 and patients answering “no” or “I
don’t remember” will be scored 0. The total score ranges
from 0 to 4.
Other outcomes
All telephone calls and attempts are registered in a data-
base to monitor the implementation in daily practice.
For every call or attempt different aspects are registered:
– date and duration of the call, number of attempts,
age and gender of patient, reasons for not calling
the patient
– Early discontinuation: did the patient start with the
medication or did he/she decide not to start?Table 2 Frequency of aspects of counselling (adapted from C
Item number
1 Did a pharmacist or pharmacy-em
2 Did a pharmacist or pharmacy-em
3 Did the pharmacist or pharmacy
4 Did the pharmacist or pharmacy– Different aspects of knowledge are assessed by the
pharmacist on a 5-point scale “Good”, “Sufficient”,
“Poor”, “Bad”, “Not discussed”
– Experiences and attitude towards medication are
assessed by the pharmacist
– Advices given during consultation
– Contact with prescribing physician in response to
consultation.
Sample size
Power calculation is focused on the primary outcome, the
proportion of adherent patients. With a type one error (α)
for a two sided test of 0.05 and a probability of rejecting
the null hypothesis of 0.80 (1-β) 294 patients per arm are
needed for demonstrating an improvement of the propor-
tion of adherent patients from 70% to 80% [32]. For cluster
randomisation a correction is needed based on the Intra-
class correlation coefficient (ICC). When using ICC = 0.02
we need at least 15 pharmacies to include at least 30 pa-
tients per group of medication for the intervention (4), so
15*30*4 = 1800 patients in the intervention arms and 1800
in the usual care arms. We expect an average response rate
of 30% on the questionnaires and with the aim to receive
at least 100 responses per arm, we estimated to invite at
least 670 patients to participate in the survey.
Statistical analysis
The primary analysis is based on the intention-to-treat
(ITT) principle e.g. in the intervention group all patients
who should have received the intervention will be in-
cluded. Patient characteristics between groups will be
compared using Student’s t-test or χ2- test. Because it is
likely that the PDC360 will not be normally distributed,
PDC360 differences between groups will be compared
using the nonparametric Mann–Whitney U test. We use
logistic multilevel analysis to study the effect on the di-
chotomous primary outcome (adherent yes or no). The
outcome of complete discontinuation will be assessed
using Cox-proportional hazards. We consider a p-value
of less than 0.05 to be statistical significant. In a second
analysis effect modification and confounding will be
assessed. Effect modification is defined as a significant
interaction (p < 0.10) between group allocation and the
variable in question. In a per-protocol (PP) analysis we
include in the intervention group only patients who ac-
tually received the call.onsumer Quality Index)
ployee ask you about your experiences with the medication?
ployee ask you if you suffered from any side effects?
-employee provide enough personal counselling?
-employee ask you if you manage to take your medication as prescribed?
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All patient data will provided to the Utrecht University
by the participating pharmacies according to a proced-
ure to protect the subjects’ privacy. Data with regard to
the patients’ identity were coded anonymous by the par-
ticipating pharmacies.
Discussion
This is the first large intervention trial in The Netherlands
to study the effect of telephone counselling by pharmacists
on adherence. Although pharmacist can play an important
role in improving adherence, in daily practice not all pa-
tients receive optimal care. The studied intervention is a
way to deliver patient-centred care. And can be a solution
to barriers in daily practice and that therefore more pa-
tients receive appropriate care. We also recognize that this
intervention might not be appropriate for every individual
patient, by including sufficient patients in 4 medication
groups we expect to gain insight into which patients bene-
fit most of this intervention.
The quality of the intervention depends on the compe-
tences and skills of the pharmacist. We try to assure treat-
ment integrity by providing an interview protocol, an
obligatory communication training and the obligation to
document every counselling-call in an online database. Al-
though it is likely that there will remain some differences
between pharmacists, our goal is not to study the effect of
an intervention in an ideal, perfectly controlled situation,
but to study it in daily practice. We believe that this in-
creases the external validity since it reflects current prac-
tice. The qualitative analysis of (a sample of) the telephone
calls, will provide more insight in the intervention as pro-
vided by different pharmacists.
The intervention focusses on patient starting treatment
and the aim of the intervention is to assess both practical
and perceptual barriers that can influence adherent behav-
iour. These barriers can both be intentional or non-
intentional and especially at the start of therapy it can be a
mix of both. Moreover a recent study suggests that unin-
tentional non-adherence is influenced by medication be-
liefs, chronic disease and socio-demographics [33]. So
before a health care provider can tailor the intervention to
intentional or non-intentional non-adherent behaviour, the
barriers should first be assessed.
Assessment of adherence will be based on pharmacy
data. Studies show that this is a valid method. In the
Netherlands most prescriptions are filled for three months,
irrespective of the frequency of dosing. Therefore, we ex-
pect to find enough contrast to assess the effect of the
intervention on refill adherence.
We will conduct this study in different pharmacies in
different regions of The Netherlands which will improve
the external validity and will make it possible to perform
an inter-pharmacy comparison.Limitations
The cluster randomized design of the study may com-
promises the internal validity of the study since differ-
ence at baseline between the levels of the provided care
between pharmacies cannot be ruled out. It is likely that
a part of the patients in the intervention groups will not
be available for the intervention, because contact details
are lacking or patients cannot be reached. Since in the
control group these patients cannot be excluded this can
cause a selection bias in the per-protocol analysis.
Conclusion
Upon completion of this study will have knowledge if and
for which group of high-risk patients, counselling by tele-
phone at the start of a pharmacotherapy is (most) effective
in improving adherence. Also will be clear how the inter-
vention affects patients’ perceptions on medication and
pharmaceutical care.
Additional files
Additional file 1: List of included medication. The table shows the
name and ATC-code of the included medication.
Additional file 2: General interview protocol. The general interview
protocol to be used in the counselling calls.
Abbreviations
ATC: Anatomical therapeutic chemical; BMQ: Beliefs about medicines
questionnaire; CQI: Consumer quality index; HBM: The health belief model;
ICC: Intraclass correlation coefficient; ITT: Intention-to-treat; PDC360: Proportion
of cays covered of 360 days period; PP: Per-protocol; SIMS: Satisfaction with
information about medicines scale; RAS: Renin-angiontensin-system.
Competing interests
The authors of this protocol disclose no financial competing interest
pertinent to this study.
Authors’ contributions
MK wrote the first draft of the manuscript. MK, MB, KG and RH participated
in the design of the trial and study methodology and review of the
manuscript. KG, LD, MB and RH made critical revisions to the manuscript.
All authors read and approved the final manuscript.
Authors’ information
Prof. Dr. M.L. Bouvy has been involved in several projects both aiming to
describe the magnitude of non-adherence, to explore reasons for patients
non-adherence and to improve medication adherence. Moreover M. Bouvy
has performed several intervention studies in community pharmacy and is
familiar with the practical problems of practice research. M. Bouvy has
extended experience with general public information about pharmacotherapy
(Books for general public: ‘Drugs in The Netherlands’, ‘The correct drug’ and
‘treat minor ailments’ in cooperation with the Consumers Board). M. Bouvy has
frequently given lectures and post graduate courses on medication adherence.
Dr. E.R. Heerdink is associate professor of clinical pharmacoepidemiology at
the division of Pharmacoepidemiology and Pharmacotherapy of Utrecht
University. He has ample experience with designing, conducting and
reporting large-scale studies on the effects of the use of medication in
patients in daily clinical practice. He has published extensively in inter-
national peer-reviewed journals (150+). Adherence with medication has
been a continuous subject of interest throughout his career. He is the
2011/2012 president of the European Society for Patient Adherence,
Compliance and Persistence.
Kooy et al. BMC Health Services Research 2014, 14:219 Page 8 of 9
http://www.biomedcentral.com/1472-6963/14/219Dr. E.C.G. van Geffen is involved in the pharmacy practice research of UPPER,
which is part of the division of Pharmacoepidemiology and
Pharmacotherapy of Utrecht University. The research mainly focuses on drug
induced problems and adherence, patient communication and education,
and patients experiences with medication use. Through the UPPER-pharmacy
research network, they have access to 900 pharmacies and their patients.
Van Geffen finished her thesis on patients’ perspectives and experiences with
antidepressant medication. From 1999 to 2008 she was also head of the
Science Shop for Medicines of Utrecht University. In 2011 Katja joined the
Dutch Kidney Foundation as Program Manager working on the early
detection of kidney damage and prevention of kidney failure.
Dr. Ir Liset van Dijk obtained her PhD-degree in sociology at Utrecht University.
She was a postdoc at the University of Arizona, the University of Michigan,
Utrecht University and Wageningen University. From 1999 onwards Liset is
employed at NIVEL, Netherlands institute for health services research in Utrecht,
where she is research coordinator of pharmaceutical care. In 2007, she joined
the Division of Pharmacoepidemiology and Pharmacotherapy at Utrecht
University as adjunct faculty. Her main research interests include: drug
utilization research, adherence to medication, international comparisons,
and policy evaluation.
M.J.Kooy, PharmD, is a pharmacist combining his care for patients in a
community pharmacy with his scientific ambitions at Utrecht University.
Since his graduation in 2003 at the University of Groningen, he works in a
modern community pharmacy, Service Apotheek Koning in Amsterdam. In
2010 he started working on his PhD thesis on the effects of interventions to
improve medication adherence. The main intervention study uses
counseling by telephone at the start at therapy as an intervention to
improve adherence. He is also involved in two different studies using an
electronic reminder device and e-health.Acknowledgements
We thank Emma Vogels-Giesen and Saskia Beckers of Service Apotheek, and the
participating pharmacies for their effort in the study. We also thank Achmea
represented by Anouk Wereldsma for their financial support of the project.
Author details
1Department of Pharmacoepidemiology & Clinical Pharmacology, Utrecht
Institute for Pharmaceutical Sciences, Utrecht University, P.O. Box 80082,
Utrecht 3508 TB, The Netherlands. 2Netherlands Institute for Health Services
Research (NIVEL), P.O. Box 1568, Utrecht 3500, BN The Netherlands.
Received: 20 August 2013 Accepted: 7 May 2014
Published: 15 May 2014References
1. Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 2005,
353(5):487–497.
2. van Geffen EC, Gardarsdottir H, van Hulten R, van Dijk L, Egberts AC,
Heerdink ER: Initiation of antidepressant therapy: do patients follow the
GP’s prescription? Br J Gen Pract 2009, 59(559):81–87.
3. WHO: ADHERENCE TO LONG-TERM THERAPIES Evidence for action. 2003,
4. Phatak HM, Thomas J 3rd: Relationships between beliefs about
medications and nonadherence to prescribed chronic medications.
Ann Pharmacother 2006, 40(10):1737–1742.
5. van Geffen EC, Kruijtbosch M, Egberts AC, Heerdink ER, van Hulten R:
Patients’ perceptions of information received at the start of selective
serotonin-reuptake inhibitor treatment: implications for community
pharmacy. Ann Pharmacother 2009, 43(4):642–649.
6. van Geffen EC, van Hulten R, Bouvy ML, Egberts AC, Heerdink ER:
Characteristics and reasons associated with nonacceptance of selective
serotonin-reuptake inhibitor treatment. Ann Pharmacother 2008,
42(2):218–225.
7. Urquhart J, Vrijens B: New findings about patient adherence to
prescribeddrug dosing regimens: an introduction to pharmionics. Eur J
Hosp Pharm Sci 2005, 5:103.
8. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T,
Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczyk M, Mshelia C,
Clyne W, Aronson JK, Urquhart J, ABC Project Team: A new taxonomy for
describing and defining adherence to medications. Br J Clin Pharmacol
2012, 73(5):691–705.9. Lamberts EJF, Bouvy ML, Hulten RP: The role of the community
pharmacist in fulfilling information needs of patients starting oral
antidiabetics. Res Soc Adm Pharm 2010, 6(4):354–364.
10. Feifer RA, Greenberg L, Rosenberg-Brandl S, Franzblau-Isaac E: Pharmacist
counseling at the start of therapy: patient receptivity to offers of in-
person and subsequent telephonic clinical support. Popul Health Manag
2010, 13(4):189–193.
11. Koo MM, Krass I, Aslani P: Factors influencing consumer use of written
drug information. Ann Pharmacother 2003, 37(2):259–267.
12. Melnyk PS, Shevchuk YM, Remillard AJ: Impact of the dial access drug
information service on patient outcome. Ann Pharmacother 2000,
34(5):585–592.
13. Kessels RP: Patients’ memory for medical information. J R Soc Med 2003,
96(5):219–222.
14. Linn AJ, van Dijk L, Smit EG, Jansen J, van Weert JC: May you never forget
what is worth remembering: the relation between recall of medical
information and medication adherence in patients with inflammatory
bowel disease. J Crohns Colitis 2013, 7(11):e543–e550.
15. Sleath B, Wurst K, Lowery T: Drug information sources and antidepressant
adherence. Community Ment Health J 2003, 39(4):359–368.
16. Arbuthnott A, Sharpe D: The effect of physician-patient collaboration on
patient adherence in non-psychiatric medicine. Patient Educ Couns 2009,
77(1):60–67.
17. Kane SV, Robinson A: Review article: understanding adherence to
medication in ulcerative colitis - innovative thinking and evolving
concepts. Aliment Pharmacol Ther 2010, 32(9):1051–1058.
18. Linn AJ, van Weert JC, Schouten BC, Smit EG, van Bodegraven AA, van Dijk L:
Words that make pills easier to swallow: a communication typology to
address practical and perceptual barriers to medication intake behavior.
Patient Prefer Adherence 2012, 6:871–885.
19. Elliott RA, Barber N, Clifford S, Horne R, Hartley E: The cost effectiveness of
a telephone-based pharmacy advisory service to improve adherence to
newly prescribed medicines. Pharm World Sci 2008, 30(1):17–23.
20. Wu JY, Leung WY, Chang S, Lee B, Zee B, Tong PC, Chan JC: Effectiveness
of telephone counselling by a pharmacist in reducing mortality in
patients receiving polypharmacy: randomised controlled trial. BMJ 2006,
333(7567):522.
21. Jones CJ, Smith HE, Frew AJ, Du Toit G, Mukhopadhyay S, Llewellyn CD:
Explaining adherence to self-care behaviours amongst adolescents with
food allergy: A comparison of the health belief model and the common
sense self-regulation model. Br J Health Psychol 2013, 19(1):65–82.
22. Rosenstock IM: Why people use health services. Milbank Mem Fund Q
1966, 44(Suppl 3):94–127.
23. Greenhill N, Anderson C, Avery A, Pilnick A: Analysis of pharmacist–patient
communication using the Calgary-Cambridge guide. Patient Educ Couns
2011, 83(3):423–431.
24. Hess LM, Raebel MA, Conner DA, Malone DC: Measurement of adherence in
pharmacy administrative databases: a proposal for standard definitions and
preferred measures. Ann Pharmacother 2006, 40(7–8):1280–1288.
25. Horne R: The Beliefs about medicines questionnaire: the development
and evaluation of a new method for assessing the cognitive
representation of medication. Psychol Health 1999, 14:1–24.
26. Aikens JE, Nease DE Jr, Nau DP, Klinkman MS, Schwenk TL: Adherence to
maintenance-phase antidepressant medication as a function of patient
beliefs about medication. Ann Fam Med 2005, 3(1):23–30.
27. Menckeberg TT, Bouvy ML, Bracke M, Kaptein AA, Leufkens HG, Raaijmakers JA,
Horne R: Beliefs about medicines predict refill adherence to inhaled
corticosteroids. J Psychosom Res 2008, 64(1):47–54.
28. Tibaldi G, Clatworthy J, Torchio E, Argentero P, Munizza C, Horne R: The
utility of the Necessity–Concerns Framework in explaining treatment
non-adherence in four chronic illness groups in Italy. Chronic Illn 2009,
5(2):129–133.
29. Horne R, Hankins M, Jenkins R: The Satisfaction with Information about
Medicines Scale (SIMS): a new measurement tool for audit and research.
Qual Health Care 2001, 10(3):135–140.
30. van Greuningen M, Vervloet M, van der Hoek L, van Dijk L: Het
discriminerend vermogen van de CQ-index Farmaceutische Zorg. 2009,
31. van Geffen EC, Philbert D, van Boheemen C, van Dijk L, Bos MB, Bouvy ML:
Patients’ satisfaction with information and experiences with counseling
on cardiovascular medication received at the pharmacy. Patient Educ
Couns 2011, 83(3):303–309.
Kooy et al. BMC Health Services Research 2014, 14:219 Page 9 of 9
http://www.biomedcentral.com/1472-6963/14/21932. Campbell MJ, Julious SA, Altman DG: Estimating sample sizes for binary,
ordered categorical, and continuous outcomes in two group
comparisons. BMJ 1995, 311(7013):1145–1148.
33. Gadkari AS, McHorney CA: Unintentional non-adherence to chronic
prescription medications: How unintentional is it really? BMC Health
Serv Res 2012, 12(1):98.
doi:10.1186/1472-6963-14-219
Cite this article as: Kooy et al.: Effects of a TELephone Counselling
Intervention by Pharmacist (TelCIP) on medication adherence, patient
beliefs and satisfaction with information for patients starting treatment:
study protocol for a cluster randomized controlled trial. BMC Health
Services Research 2014 14:219.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
